How effective is Mitotane in the treatment of adrenocortical cancer?

Adrenocortical Carcinoma (Adrenocortical Carcinoma,ACC) is a rare but aggressive cancer that originates in the adrenal cortex tissue. There are a variety of treatments for ACC, including surgery, radiation therapy, chemotherapy, and targeted therapy. Mitotane (Mitotane), also known as Lysodren (Lysodren), is a hormone disruptor that is widely used in the treatment of ACC. This article will explore the effect of mitotane in the treatment of ACC and discuss it based on clinical experimental data.

Mitotan’s mechanism of action:

Mitotan is a drug whose main function is to destroy the function of adrenocortical cells, thereby inhibiting the secretion of adrenocortical hormones and reducing the growth rate of tumor cells. ACCIt is often accompanied by excessive secretion of adrenocortical hormones, so by reducing the levels of these hormones, mitotane can help reduce patients' symptoms such as hypertension, metabolic disorders and other problems related to excessive corticosteroids.

Clinical trial data:

Many studies and clinical trials have evaluated the effectiveness of mitotane in the treatment ofACC. Below is a summary of some key study results and clinical data:

1.Prolonged survival: The use of mitotane has been shown to be associated with prolonged survival of ACC patients. In some studies, patients taking mitotane lived significantly longer, especially if the tumor had not spread to other sites or was unresectable with surgery.

2.Control tumor growth: Mitotan can help slow the growth of adrenocortical cancer. Studies have shown that mitotane can inhibit the proliferation of tumor cells and thereby control tumor progression.

3.Reducing symptoms: Excessive secretion of corticosteroids usually causes patients to develop symptoms such as high blood pressure, obesity, and mood swings. Mitotane can help reduce these symptoms and improve patients' quality of life.

4.Combined treatment: In some studies, mitotane is often combined with other treatments such as surgery, radiation therapy, and chemotherapy to increase the effectiveness of the treatment. Comprehensive treatment strategies can be tailored to the patient's specific circumstances.

Although mitotane has shown some efficacy in the treatment ofACC, there are some challenges and potential side effects. Mitotane use may be associated with nausea, vomiting, diarrhea, skin pigmentation, and other discomforts. In addition, the response to treatment varies between patients, and some patients may respond poorly to mitotane treatment or develop drug resistance.

Thus, treatmentACCoften requires a comprehensive treatment strategy from a multidisciplinary team, including specialized physicians, surgeons, oncologists, and other medical professionals. Treatment plans should be customized to the patient's specific circumstances and adjusted as the disease progresses. Patients should work closely with their doctor while taking mitotane for optimal treatment effectiveness and safety. ACCis a serious cancer whose treatment is often complex and requires patients to be treated under the supervision of a professional medical team.

Mitotane has not yet been launched in China, so patients cannot purchase it domestically and need to purchase it through overseas channels. There are original drugs and generic drugs abroad. The Turkish version of the original drug is about more than 7,000 yuan, followed by the European version of the original drug, which is about 9,000 yuan. There are also cost-effective generic drugs, mainly Laos and ASEAN generic drugs. The price is about more than 3,000 yuan. The ingredients of the original drugs and generic drugs are the same.